BR0016135A - Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto - Google Patents
Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um compostoInfo
- Publication number
- BR0016135A BR0016135A BR0016135-7A BR0016135A BR0016135A BR 0016135 A BR0016135 A BR 0016135A BR 0016135 A BR0016135 A BR 0016135A BR 0016135 A BR0016135 A BR 0016135A
- Authority
- BR
- Brazil
- Prior art keywords
- particle size
- compound
- reduced
- reduced particle
- conditions associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"FORMA DE TAMANHO DE PARTìCULA REDUZIDO, USO DE UMA SUBSTâNCIA, COMPOSIçãO FARMACêUTICA, MéTODOS PARA O TRATAMENTO OU A PROFILAXIA DE CONDIçõES ASSOCIADAS COM REDUZIDA SENSIBILIDADE à INSULINA E DE DESLIPIDEMIA, DIABETES MELITO DO TIPO H, HIPERGLICEMIA, HIPERINSULINEMIA, HIPERTENSãO ARTERIAL E/OU OBESIDADE ABDOMINAL E PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A presente invenção refere-se a uma forma de tamanho de partícula reduzido do composto ácido (S)-2-etoxi-3-[4-(2-{4-metanossulfoniloxifenil}etoxi)fenil]propanóico, como mostrado na fórmula (I) ou um seu sal farmaceuticamente aceitável ou qualquer um de seu solvato. A invenção também se refere a um método de tratamento de uma ou mais condições associadas com a Síndrome de Resistência à Insulina usando a forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável na manufatura de um medicamento para uso em uma ou mais das citadas condições. A invenção refere-se adicionalmente às composições farmacêuticas contendo a forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável, ou de um seu solvato, como um ingrediente ativo, bem como a um processo para a manufatura da forma de tamanho de partícula reduzido do composto, ou de um seu sal farmaceuticamente aceitável.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9904413A SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Comminuted form |
| PCT/SE2000/002381 WO2001040169A1 (en) | 1999-12-03 | 2000-11-29 | Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0016135A true BR0016135A (pt) | 2002-08-20 |
Family
ID=20417978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0016135-7A BR0016135A (pt) | 1999-12-03 | 2000-11-29 | Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1237854B1 (pt) |
| JP (1) | JP2003515580A (pt) |
| KR (1) | KR20020067538A (pt) |
| CN (1) | CN1216859C (pt) |
| AR (1) | AR029456A1 (pt) |
| AT (1) | ATE251131T1 (pt) |
| AU (1) | AU766036B2 (pt) |
| BR (1) | BR0016135A (pt) |
| CA (1) | CA2392029A1 (pt) |
| CO (1) | CO5271736A1 (pt) |
| CZ (1) | CZ20021839A3 (pt) |
| DE (1) | DE60005710T2 (pt) |
| DK (1) | DK1237854T3 (pt) |
| EE (1) | EE200200284A (pt) |
| ES (1) | ES2208444T3 (pt) |
| HK (1) | HK1049324B (pt) |
| HU (1) | HUP0203692A3 (pt) |
| IL (1) | IL149516A0 (pt) |
| IS (1) | IS6399A (pt) |
| MX (1) | MXPA02005165A (pt) |
| MY (1) | MY125099A (pt) |
| NO (1) | NO20022591D0 (pt) |
| NZ (1) | NZ518926A (pt) |
| PL (1) | PL355372A1 (pt) |
| PT (1) | PT1237854E (pt) |
| RU (1) | RU2248966C2 (pt) |
| SE (1) | SE9904413D0 (pt) |
| SK (1) | SK7662002A3 (pt) |
| TR (1) | TR200400003T4 (pt) |
| UA (1) | UA73959C2 (pt) |
| WO (1) | WO2001040169A1 (pt) |
| ZA (1) | ZA200203797B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| BR9812772A (pt) | 1997-10-27 | 2000-10-10 | Reddy Research Foundation | "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos" |
| CA2307068C (en) | 1997-10-27 | 2007-04-10 | Dr. Reddy's Laboratories Limited | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| EP1124807A1 (en) | 1997-10-27 | 2001-08-22 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| US6531596B1 (en) | 1998-10-29 | 2003-03-11 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of new antidiabetic agents |
| UA60386C2 (uk) | 1998-10-29 | 2003-10-15 | Reddys Laboratories Ltd | Спосіб одержання похідних 3-[4-[2-(феноксазин-10-іл)метокси]феніл]пропіонової кислоти (варіанти) та проміжні сполуки для їх отримання |
| US6897199B2 (en) | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1586573B1 (en) | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| MEP8509A (en) | 2006-09-07 | 2011-12-20 | Combination treatment for diabetes mellitus | |
| AU2008221673B2 (en) | 2007-03-08 | 2013-03-28 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| PT2152663E (pt) | 2007-06-04 | 2014-06-03 | Univ Ben Gurion | Compostos de triarilo e composições que compreendem os mesmos |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| EP3065723B1 (en) | 2013-11-05 | 2020-09-23 | Ben Gurion University of the Negev Research and Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| SE9704873D0 (sv) * | 1997-12-23 | 1997-12-23 | Astra Ab | Sampling apparatus |
| MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
-
1999
- 1999-12-03 SE SE9904413A patent/SE9904413D0/xx unknown
-
2000
- 2000-11-29 HU HU0203692A patent/HUP0203692A3/hu unknown
- 2000-11-29 ES ES00983616T patent/ES2208444T3/es not_active Expired - Lifetime
- 2000-11-29 UA UA2002053989A patent/UA73959C2/uk unknown
- 2000-11-29 TR TR2004/00003T patent/TR200400003T4/xx unknown
- 2000-11-29 NZ NZ518926A patent/NZ518926A/en unknown
- 2000-11-29 CA CA002392029A patent/CA2392029A1/en not_active Abandoned
- 2000-11-29 CZ CZ20021839A patent/CZ20021839A3/cs unknown
- 2000-11-29 WO PCT/SE2000/002381 patent/WO2001040169A1/en not_active Ceased
- 2000-11-29 IL IL14951600A patent/IL149516A0/xx unknown
- 2000-11-29 AU AU20348/01A patent/AU766036B2/en not_active Ceased
- 2000-11-29 DE DE60005710T patent/DE60005710T2/de not_active Expired - Fee Related
- 2000-11-29 RU RU2002113169/04A patent/RU2248966C2/ru not_active IP Right Cessation
- 2000-11-29 DK DK00983616T patent/DK1237854T3/da active
- 2000-11-29 PT PT00983616T patent/PT1237854E/pt unknown
- 2000-11-29 SK SK766-2002A patent/SK7662002A3/sk unknown
- 2000-11-29 JP JP2001541856A patent/JP2003515580A/ja not_active Withdrawn
- 2000-11-29 HK HK03101434.9A patent/HK1049324B/en not_active IP Right Cessation
- 2000-11-29 BR BR0016135-7A patent/BR0016135A/pt not_active IP Right Cessation
- 2000-11-29 EP EP00983616A patent/EP1237854B1/en not_active Expired - Lifetime
- 2000-11-29 MX MXPA02005165A patent/MXPA02005165A/es active IP Right Grant
- 2000-11-29 PL PL00355372A patent/PL355372A1/xx not_active Application Discontinuation
- 2000-11-29 KR KR1020027007058A patent/KR20020067538A/ko not_active Ceased
- 2000-11-29 AT AT00983616T patent/ATE251131T1/de not_active IP Right Cessation
- 2000-11-29 CN CN008163839A patent/CN1216859C/zh not_active Expired - Fee Related
- 2000-11-29 EE EEP200200284A patent/EE200200284A/xx unknown
- 2000-11-30 MY MYPI20005601A patent/MY125099A/en unknown
- 2000-11-30 CO CO00091759A patent/CO5271736A1/es not_active Application Discontinuation
- 2000-12-01 AR ARP000106384A patent/AR029456A1/es unknown
-
2002
- 2002-05-13 ZA ZA200203797A patent/ZA200203797B/en unknown
- 2002-05-28 IS IS6399A patent/IS6399A/is unknown
- 2002-05-31 NO NO20022591A patent/NO20022591D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0016131A (pt) | Forma cristalina, formulação farmacêutica, uso de uma forma cristalina, uso de uma substância, métodos para tratamento ou a profilaxia de, condições associadas com reduzida sensibilidade à insulina, e de deslipidemia, diabetes melito do tipo 2, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal, e , processo para a preparação de uma forma cristalina de um composto de fórmula i | |
| EP0427247B1 (de) | Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure | |
| ES2284212T3 (es) | Tratamiento de diabetes con tiazolidinadiona y metformina. | |
| BR0211665A (pt) | Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto | |
| BR0317458A (pt) | EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica | |
| EA200800198A1 (ru) | Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида | |
| NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
| BRPI0616324A2 (pt) | formulaÇço de cÁpsula de pirfenidona e excipientes farmaceuticamente aceitÁveis | |
| BRPI0513824A (pt) | derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| SE9904413D0 (sv) | Comminuted form | |
| EA022890B1 (ru) | Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их применения | |
| BRPI0111142B1 (pt) | Use of derivatives of biguanide or of its pharmaceutically acceptable salts thereof for manufacture of a medicinal product having a healing effect | |
| BRPI0407303A (pt) | Composição farmacêutica | |
| BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
| BR0317359A (pt) | Uso de ácidos alfa-feniltiocarboxìlico e alfa-feniloxicarboxìlico com atividade de diminuição de glicose no soro e diminuição de lipìdios no soro | |
| PT1704860E (pt) | Derivados de benzamidina para o tratamento e prevenção da mucosite | |
| BR0017206A (pt) | Composições sinergìsticas contendo base colina e ácido succìnico para resistência a insulina e diabetes | |
| EP3556349A1 (en) | Parenteral liquid preparation comprising carbamate compound | |
| KR20080111021A (ko) | 철 대사 장애의 치료를 위한 스트로빌루린의 용도 | |
| CN1044400A (zh) | 哌啶子基链烷醇衍生物的液体药物组合物 | |
| JP2007509946A5 (pt) | ||
| JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
| KR950032191A (ko) | 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도 | |
| CN113679728B (zh) | 一种磺胺类化合物及其在制备治疗糖尿病和并发症药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |